About: Development of VHH Antibodies against Dengue Virus Type 2 NS1 and Comparison with Monoclonal Antibodies for Use in Immunological Diagnosis

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Development of VHH Antibodies against Dengue Virus Type 2 NS1 and Comparison with Monoclonal Antibodies for Use in Immunological Diagnosis Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Development of VHH Antibodies against Dengue Virus Type 2 NS1 and Comparison with Monoclonal Antibodies for Use in Immunological Diagnosis
Creator	Xia, L Wang, Y Wang, H Fatima, A Kang, K
Source	PMC
abstract	The possibility of using variable domain heavy-chain antibodies (VHH antibodies) as diagnostic tools for dengue virus (DENV) type 2 NS1 protein was investigated and compared with the use of conventional monoclonal antibodies. After successful expression of DENV type 2 NS1 protein, the genes of VHH antibodies against NS1 protein were biopanned from a non-immune llama library by phage display. VHH antibodies were then expressed and purified from Escherichia coli. Simultaneously, monoclonal antibodies were obtained by the conventional route. Sequence analysis of the VHH antibodies revealed novel and long complementarity determining regions 3 (CDR3). Epitope mapping was performed via a phage display peptide library using purified VHH and monoclonal antibodies as targets. Interestingly, the same region of NS1, which comprises amino acids (224)HWPKPHTLW(232), was conserved for both kinds of antibodies displaying the consensus motif histidine-tryptophan-tryptophan or tryptophan-proline-tryptophan. The two types of antibodies were used to prepare rapid diagnostic kits based on immunochromatographic assay. The VHH antibody immobilized rapid diagnostic kit showed better sensitivity and specificity than the monoclonal antibody immobilized rapid diagnostic kit, which might be due to the long CDR3 regions of the VHH antibodies and their ability to bind to the pocket and cleft of the targeted antigen. This demonstrates that VHH antibodies are likely to be an option for developing point-of-care tests against DENV infection.
has issue date	2014-04-21(xsd:dateTime)
bibo:doi	10.1371/journal.pone.0095263
bibo:pmid	24751715
has license	cc-by
sha1sum (hex)	aca7762f80af606fe3c6d2614096db74f1398368
schema:url	https://doi.org/10.1371/journal.pone.0095263
resource representing a document's title	Development of VHH Antibodies against Dengue Virus Type 2 NS1 and Comparison with Monoclonal Antibodies for Use in Immunological Diagnosis
has PubMed Central identifier	PMC3994031
has PubMed identifier	24751715
schema:publication	PLoS One
resource representing a document's body	covid:aca7762f80af606fe3c6d2614096db74f1398368#body_text
is schema:about of	named entity 'immobilized' named entity 'antibody' named entity 'possibility' named entity 'type' named entity 'antibodies' named entity 'based' named entity 'protein' named entity 'compared' named entity 'purified' named entity 'investigated' named entity 'Development' named entity 'DENGUE VIRUS TYPE 2' named entity 'EXPRESSION' named entity 'ASSAY' named entity 'ROUTE' named entity 'TOOLS' named entity 'USE' named entity 'CONSERVED' named entity 'USING' covid:arg/aca7762f80af606fe3c6d2614096db74f1398368 named entity 'SIMULTANEOUSLY' named entity 'ANTIGEN' named entity 'LIKELY' named entity 'EXPRESSED' named entity 'DISPLAYING' named entity 'SENSITIVITY AND SPECIFICITY' named entity 'TYPES' named entity 'CLEFT' named entity 'PURIFIED' named entity 'COMPARED' named entity 'PHAGE DISPLAY PEPTIDE LIBRARY' named entity 'AMINO ACIDS' named entity 'IMMUNOLOGICAL DIAGNOSIS' named entity 'MONOCLONAL ANTIBODIES' named entity 'IMMUNE' named entity 'LIBRARY' named entity 'SEQUENCE ANALYSIS' named entity 'TESTS' named entity 'CDR3' named entity 'MONOCLONAL ANTIBODIES' named entity 'COMPARISON' named entity 'ANTIBODIES' named entity 'DEVELOPMENT' named entity 'NS1' named entity 'RAPID DIAGNOSTIC KIT' named entity 'TRYPTOPHAN' named entity 'USED' named entity 'DOMAIN' named entity 'DIAGNOSTIC' named entity 'NS1 PROTEIN' named entity 'NOVEL' named entity 'THEIR' named entity '232' named entity 'CONSENSUS' named entity 'DEVELOPING' named entity 'VARIABLE' named entity 'PROLINE' named entity 'TO PREPARE' named entity '224' named entity 'DUE TO' named entity 'POSSIBILITY OF' named entity 'POINT-OF-CARE' named entity 'MOTIF' named entity 'ESCHERICHIA COLI' named entity 'PROTEIN ' named entity 'INVESTIGATED' named entity 'REVEALED' named entity 'SUCCESSFUL' named entity 'PHAGE DISPLAY' named entity 'KINDS' named entity 'REGION' named entity 'TARGETS' named entity 'COMPLEMENTARITY DETERMINING REGIONS' named entity 'NS1' named entity 'CONVENTIONAL' named entity 'BASED' named entity 'MONOCLONAL ANTIBODY'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software